Market Overview:
The global tubulin inhibitors for breast cancer market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of breast cancer, rising awareness about available treatment options, and technological advancements in the field of oncology. The global tubulin inhibitors for breast cancer market is segmented by type into eribulin, ixabepilone, docetaxel, trastuzumab emtansine (T-DM1), utidelone, paclitaxel, liposome paclitaxel and protein-bound paclitaxel. By application, the market is segmented into hospitals, clinics Drug centers and other applications.
Product Definition:
Tubulin inhibitors are a class of drugs that block the formation of microtubules in cancer cells, disrupting their ability to divide and grow. This can lead to tumor cell death. Tubulin inhibitors are used to treat a variety of cancers, including breast cancer.
Eribulin:
Eribulin is a small molecule that inhibits the growth of cancer cells. Blocking these pathways results in the inhibition of cell proliferation as well as migration.
Ixabepilone:
Ixabepilone is a novel drug developed by Bayer and has shown to be effective in vitro & in vivo. It's mechanism of action is believed to be via inhibition of the binding of cyclic adenosine monophosphate (cAMP) which results in reduced protein synthesis.
Application Insights:
The other application segment held the largest share of over 70.0% in 2017 owing to the high incidence of non-small cell lung cancer and breast cancer. The use of tubulin inhibitors for this purpose is relatively new, thus there are very few clinical data available for this application segment. However, these drugs show potential as second line therapy for patients with resistant tumors after first line chemotherapy has failed or not worked properly. Thus, they are expected to gain significant market share during the forecast period owing to their effectiveness against a wide range of cancers coupled with their ability to act as second line therapy after first line chemotherapy has failed or not worked properly.
In addition, these drugs exhibit excellent anti-tumor activity in vitro and in vivo which makes them an attractive option among others when it comes to treating various types of cancers such as lung adenocarcinoma and breast carcinoma (favorable).
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of key manufacturers and a well-established healthcare infrastructure. Moreover, rising incidence rates of breast cancer are expected to fuel regional growth over the forecast period. Asia Pacific is estimated to be the fastest-growing region during the forecast period due to untapped opportunities and rapidly improving healthcare infrastructure in emerging countries such as China, India, South Korea & Japan. Furthermore, increasing awareness about early diagnosis among patients is also anticipated to drive regional growth over the next eight years.
In September 2016; Ixabepilone was granted accelerated approval by FDA for treatment of locally recurrent or metastatic breast cancer following failure of anthracycline therapy or hormonal therapy including aromatase inhibitors or selective estrogen receptor modulators (SERMs).
Growth Factors:
- Increasing incidence of breast cancer
- Rising awareness about the benefits of Tubulin Inhibitors for Breast Cancer treatment
- Technological advancements in the field of breast cancer treatment
- Availability of government funding for research on Tubulin Inhibitors for Breast Cancer
- Growing number of clinical trials evaluating the efficacy and safety profile of Tubulin Inhibitors for Breast Cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Tubulin Inhibitors for Breast Cancer Market Research Report
By Type
Eribulin, Ixabepilone, Docetaxel, Trastuzumab Emtansine, Utidelone, Paclitaxel, Liposome Paclitaxel, Protein-bound Paclitaxel
By Application
Hospital, Clinic, Drug Center, Other
By Companies
Eisai, Bristol-Myers Squibb, Otsuka Pharmaceutical, Hengrui Medicine, Sanofi, Qilu Pharma, Shenzhen Main Luck Pharma, Jiangsu Aosaikang Pharma, Genentech, Beijing Biostar Technologies, Celgene Corporation, Hospira, Biological E., Taj Accura, Khandelwal Laboratories, Luye Pharma, Beijing Youcare, Beijing Union, Haiyao, Chuntch, CSPC Pharmaceutical, Aosaikang Pharm
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
187
Number of Tables & Figures
131
Customization Available
Yes, the report can be customized as per your need.
Global Tubulin Inhibitors for Breast Cancer Market Report Segments:
The global Tubulin Inhibitors for Breast Cancer market is segmented on the basis of:
Types
Eribulin, Ixabepilone, Docetaxel, Trastuzumab Emtansine, Utidelone, Paclitaxel, Liposome Paclitaxel, Protein-bound Paclitaxel
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Drug Center, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eisai
- Bristol-Myers Squibb
- Otsuka Pharmaceutical
- Hengrui Medicine
- Sanofi
- Qilu Pharma
- Shenzhen Main Luck Pharma
- Jiangsu Aosaikang Pharma
- Genentech
- Beijing Biostar Technologies
- Celgene Corporation
- Hospira
- Biological E.
- Taj Accura
- Khandelwal Laboratories
- Luye Pharma
- Beijing Youcare
- Beijing Union
- Haiyao
- Chuntch
- CSPC Pharmaceutical
- Aosaikang Pharm
Highlights of The Tubulin Inhibitors for Breast Cancer Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Eribulin
- Ixabepilone
- Docetaxel
- Trastuzumab Emtansine
- Utidelone
- Paclitaxel
- Liposome Paclitaxel
- Protein-bound Paclitaxel
- By Application:
- Hospital
- Clinic
- Drug Center
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Tubulin Inhibitors for Breast Cancer Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Tubulin inhibitors are medications that block the activity of tubulin, a protein in cells that helps them move around. Tubulin inhibitors can help to stop the growth of cancer cells by stopping their ability to divide.
Some of the major players in the tubulin inhibitors for breast cancer market are Eisai, Bristol-Myers Squibb, Otsuka Pharmaceutical, Hengrui Medicine, Sanofi, Qilu Pharma, Shenzhen Main Luck Pharma, Jiangsu Aosaikang Pharma, Genentech, Beijing Biostar Technologies, Celgene Corporation, Hospira, Biological E., Taj Accura, Khandelwal Laboratories, Luye Pharma, Beijing Youcare, Beijing Union, Haiyao, Chuntch, CSPC Pharmaceutical, Aosaikang Pharm.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Tubulin Inhibitors for Breast Cancer Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Tubulin Inhibitors for Breast Cancer Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Tubulin Inhibitors for Breast Cancer Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Tubulin Inhibitors for Breast Cancer Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Tubulin Inhibitors for Breast Cancer Market Size & Forecast, 2018-2028
4.5.1 Tubulin Inhibitors for Breast Cancer Market Size and Y-o-Y Growth
4.5.2 Tubulin Inhibitors for Breast Cancer Market Absolute $ Opportunity
Chapter 5 Global Tubulin Inhibitors for Breast Cancer Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Tubulin Inhibitors for Breast Cancer Market Size Forecast by Type
5.2.1 Eribulin
5.2.2 Ixabepilone
5.2.3 Docetaxel
5.2.4 Trastuzumab Emtansine
5.2.5 Utidelone
5.2.6 Paclitaxel
5.2.7 Liposome Paclitaxel
5.2.8 Protein-bound Paclitaxel
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Tubulin Inhibitors for Breast Cancer Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Tubulin Inhibitors for Breast Cancer Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Drug Center
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Tubulin Inhibitors for Breast Cancer Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Tubulin Inhibitors for Breast Cancer Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Tubulin Inhibitors for Breast Cancer Analysis and Forecast
9.1 Introduction
9.2 North America Tubulin Inhibitors for Breast Cancer Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Tubulin Inhibitors for Breast Cancer Market Size Forecast by Type
9.6.1 Eribulin
9.6.2 Ixabepilone
9.6.3 Docetaxel
9.6.4 Trastuzumab Emtansine
9.6.5 Utidelone
9.6.6 Paclitaxel
9.6.7 Liposome Paclitaxel
9.6.8 Protein-bound Paclitaxel
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Tubulin Inhibitors for Breast Cancer Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Drug Center
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Tubulin Inhibitors for Breast Cancer Analysis and Forecast
10.1 Introduction
10.2 Europe Tubulin Inhibitors for Breast Cancer Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Tubulin Inhibitors for Breast Cancer Market Size Forecast by Type
10.6.1 Eribulin
10.6.2 Ixabepilone
10.6.3 Docetaxel
10.6.4 Trastuzumab Emtansine
10.6.5 Utidelone
10.6.6 Paclitaxel
10.6.7 Liposome Paclitaxel
10.6.8 Protein-bound Paclitaxel
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Tubulin Inhibitors for Breast Cancer Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Drug Center
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Tubulin Inhibitors for Breast Cancer Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Tubulin Inhibitors for Breast Cancer Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Tubulin Inhibitors for Breast Cancer Market Size Forecast by Type
11.6.1 Eribulin
11.6.2 Ixabepilone
11.6.3 Docetaxel
11.6.4 Trastuzumab Emtansine
11.6.5 Utidelone
11.6.6 Paclitaxel
11.6.7 Liposome Paclitaxel
11.6.8 Protein-bound Paclitaxel
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Tubulin Inhibitors for Breast Cancer Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Drug Center
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Tubulin Inhibitors for Breast Cancer Analysis and Forecast
12.1 Introduction
12.2 Latin America Tubulin Inhibitors for Breast Cancer Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Tubulin Inhibitors for Breast Cancer Market Size Forecast by Type
12.6.1 Eribulin
12.6.2 Ixabepilone
12.6.3 Docetaxel
12.6.4 Trastuzumab Emtansine
12.6.5 Utidelone
12.6.6 Paclitaxel
12.6.7 Liposome Paclitaxel
12.6.8 Protein-bound Paclitaxel
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Tubulin Inhibitors for Breast Cancer Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Drug Center
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Tubulin Inhibitors for Breast Cancer Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Tubulin Inhibitors for Breast Cancer Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Tubulin Inhibitors for Breast Cancer Market Size Forecast by Type
13.6.1 Eribulin
13.6.2 Ixabepilone
13.6.3 Docetaxel
13.6.4 Trastuzumab Emtansine
13.6.5 Utidelone
13.6.6 Paclitaxel
13.6.7 Liposome Paclitaxel
13.6.8 Protein-bound Paclitaxel
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Tubulin Inhibitors for Breast Cancer Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Drug Center
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Tubulin Inhibitors for Breast Cancer Market: Competitive Dashboard
14.2 Global Tubulin Inhibitors for Breast Cancer Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eisai
14.3.2 Bristol-Myers Squibb
14.3.3 Otsuka Pharmaceutical
14.3.4 Hengrui Medicine
14.3.5 Sanofi
14.3.6 Qilu Pharma
14.3.7 Shenzhen Main Luck Pharma
14.3.8 Jiangsu Aosaikang Pharma
14.3.9 Genentech
14.3.10 Beijing Biostar Technologies
14.3.11 Celgene Corporation
14.3.12 Hospira
14.3.13 Biological E.
14.3.14 Taj Accura
14.3.15 Khandelwal Laboratories
14.3.16 Luye Pharma
14.3.17 Beijing Youcare
14.3.18 Beijing Union
14.3.19 Haiyao
14.3.20 Chuntch
14.3.21 CSPC Pharmaceutical
14.3.22 Aosaikang Pharm
